birinapant: Clinical Trials

7 trials of birinapant, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 terminated, 2 completed, 1 withdrawn. 7 Phase 2, 5 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 27Terminated 4, Completed 2, Withdrawn 1
Phase 15Completed 2, Terminated 2, Withdrawn 1

Follow birinapant: new trials by email Literature Review of birinapant trials Research Report on birinapant

Trials (filtered) newest first · largest first

All 7 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Birinapant and Carboplatin in Treating Patients and Targeting Recurrent High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (HGSOC)
Birinapant, Carboplatin, Laboratory Biomarker Analysis - High Grade Fallopian Tube Serous Adenocarcinoma, High Grade Ovarian Serous Adenocarcinoma
Phase 1 / Phase 2WithdrawnJonsson Comprehensive Cancer Center2018-08-012025-05-13
Dose-escalation Study of Birinapant and Pembrolizumab in Solid Tumors
Birinapant, Pembrolizumab - Solid Tumors
Phase 1 / Phase 2TerminatedMedivir342017-08-042021-01-14
Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL
birinapant, Azacitidine, Placebo - Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML)
Phase 2TerminatedTetraLogic Pharmaceuticals1182014-06-012016-10-20
Birinapant With 5-azacitidine in MDS Subjects Who Are Naïve, Have Relapsed or Are Refractory to 5-azacitidine Therapy
Birinapant, 5-Azacitidine - Myelodysplastic Syndrome
Phase 1 / Phase 2CompletedTetraLogic Pharmaceuticals212013-06-012016-04-21
Birinapant for Advanced Ovarian, Fallopian Tube, and Peritoneal Cancer
Birinapant (TL32711) - Epithelial Ovarian Cancer, Peritoneal Neoplasms
Phase 2TerminatedNational Cancer Institute (NCI)112012-08-152017-05-30
A Phase I-II Open Label Non-Randomized Study Using TL32711 for Patients With Acute Myelogenous Leukemia, Myelodysplastic Syndrome and Acute Lymphoblastic Leukemia
Birinapant - Acute Myelogenous Leukemia
Phase 1 / Phase 2TerminatedAbramson Cancer Center at Penn Medicine272011-11-012021-06-24
Dose Escalation, Combination Chemotherapy Safety Study of Birinapant (TL32711), in Subjects With Advanced or Metastatic Solid Tumors
Birinapant - Cancer
Phase 1 / Phase 2CompletedTetraLogic Pharmaceuticals1762010-10-012016-05-30

Conditions studied

Fallopian Tube Neoplasms (2)  ·  Myelodysplastic Syndromes (2)  ·  Recurrence (2)  ·  Carcinoma, Ovarian Epithelial (1)  ·  Leukemia, Myeloid, Acute (1)  ·  Leukemia, Myelomonocytic, Chronic (1)  ·  Neoplasms (1)  ·  Ovarian Neoplasms (1)  ·  Peritoneal Neoplasms (1)

Sponsors

TetraLogic Pharmaceuticals (3)  ·  Abramson Cancer Center at Penn Medicine (1)  ·  Jonsson Comprehensive Cancer Center (1)  ·  Medivir (1)  ·  National Cancer Institute (NCI) (1)

Countries

United States (7)  ·  Australia (1)  ·  Germany (1)  ·  Spain (1)

Top investigators

Alex Adjei, MD, PhD (1)  ·  Christina M Annunziata, M.D. (1)  ·  Gautam Borthakur, MD (1)  ·  John N Nemunaitis, MD (1)  ·  Kyriakos P Papadopoulos, MD (1)  ·  Lainie P Martin, MD (1)  ·  Noelle Frey, MD (1)  ·  Patricia LoRusso, DO (1)  ·  Ravi Amaravadi, MD (1)  ·  Sanaz Memarzadeh (1)  ·  Zdenka Segota, MD (1)

NIH funding

2014 (1)